NCT06860386View on ClinicalTrials.gov

Study of Adaptive Immunotherapy With VEGFR-TKI in Patients With Advanced RCC

PHASE2RecruitingINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

February 25, 2025

Primary Completion Date

February 29, 2028

Study Completion Date

February 29, 2028

Conditions
Renal Cell CarcinomaClear Cell Renal Cell Carcinoma
Interventions
DRUG

Pembrolizumab

200 mg every 3 weeks IV infusion (Q3W + or -3 days)

DRUG

Axitinib

5 mg twice daily (BID) by mouth

Trial Locations (1)

33612

RECRUITING

Moffitt Cancer Center, Tampa

All Listed Sponsors
lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER